Featured Articles
-
Pricing For Rare Disease Therapies And Cures: What’s Fair?
5/6/2024
What is a "fair" price for a curative rare disease therapy, or an effective but chronic rare disease therapy? Charles River Associates surveyed U.S. payers, before and after COVID, to find out.
-
Building On Direct-To-Patient Marketing For Improved Access To Therapeutics
5/2/2024
PA Consulting identifies the top three questions that biopharmaceutical companies should consider before launching a direct-to-patient platform and service offering.
-
Where Are They Now? SQZ Biotech
5/1/2024
SQZ Biotech, a novel cell therapy company with Big Pharma backing, is no more. However, the company's science, and its founding CEO, will continue on under new auspices.
-
Take-Home Microdosing Trial Studies Sub-Hallucinogenic For Depression
4/30/2024
MindBio Therapeutics CEO Justin Hanka details the company’s Phase 2a clinical trial investigating the use of a take-home microdosing regimen for depression.
-
Reviva Pharma’s Novel Funding Approach In Schizophrenia
4/25/2024
Reviva Pharma CEO Laxminarayan Bhat, Ph.D. found a novel way to build an investor base for his company during a time when Big Pharma was exiting complicated CNS diseases. Now, Reviva has a late-stage schizophrenia candidate just as CNS is back in vogue.
-
Companies To Watch: OSE Immunotherapeutics
4/22/2024
OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need.
-
A Deeper Look At What's Driving Dependence On Biotech Contract Manufacturers
4/19/2024
Are you struggling to find CDMO capacity? Here are some of the drivers behind the contract manufacturing market's exponential growth.
-
Navigating Growth In Biotech: A First-Person Insight
4/19/2024
Five attributes are essential for emerging biotech companies to thrive and grow in what will be a challenging financing environment for the foreseeable future. These attributes also serve as a proxy for creating long-term, sustainable value.
-
Michigan No Longer A Safe Haven For Pharmaceutical Companies?
4/17/2024
A recent change to Michigan's product liability law could have national implications. Experts at Sidley Austin detail the changes in Michigan, and explain what it could mean for pharmaceutical companies marketing products in Michigan and beyond.
-
Continuing Down The Road To BioPharma Board Diversification
4/12/2024
Diversification in the boardroom improves the quality of board performance, encourages objectivity, and expands the quality of debate and decision making. Biopharmaceutical industry boardrooms are making progress, but still have work to do.